AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

PURPOSE: Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab. METHODS: A phase III, multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonard, John P., Trneny, Marek, Izutsu, Koji, Fowler, Nathan H., Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S., Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W., Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035866/
https://www.ncbi.nlm.nih.gov/pubmed/30897038
http://dx.doi.org/10.1200/JCO.19.00010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035866/
https://www.ncbi.nlm.nih.gov/pubmed/30897038
http://dx.doi.org/10.1200/JCO.19.00010

Ejemplares similares